1.-**67**. (canceled)

68. A composition comprising at least one pharmaceutical excipient and N-(3-aminopropyl)-N—[(R)-(1-3-benzyl-7-chloro-4-oxo-4H-chromen-2-yl)-2-methyl-propyl]-4-methyl-benzamide hydrochloride hydrate.

69. The composition of claim **68**, wherein the composition further comprises a chemotherapeutic agent other than N-(3-aminopropyl)-N—[(R)-(1-3-benzyl-7-chloro-4-oxo-4H-chromen-2-yl)-2-methyl-propyl]-4-methyl-benzamide hydrochloride hydrate.

70. The composition of claim **68** wherein the composition is formulated for administration by a route chosen from oral, subcutaneous, intravenous, intranasal, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, and intraocular.

71. The composition of claim **70** wherein the composition is formulated for oral administration.

72. The composition of claim **71** wherein the composition is formulated as a tablet, capsule, or liquid.

73. The composition of claim **71** wherein the at least one pharmaceutical excipient is selected from diluents, binders, glidants, lubricants, disintegrants, colors, flavors, sweetening agents, polymers, waxes and other solubility-retarding materials.

74. The composition of claim **70** wherein the composition is formulated for intravenous administration.

75. The composition of claim **74** wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes.

76. The composition of claim **74** wherein the at least one pharmaceutical excipient is water for injection USP.

77. The composition of claim **68** wherein the composition is formulated for parenteral administration.

78. The composition of claim **77** wherein the at least one pharmaceutical excipient comprises a sterile solution of sugars, amino acids or electrolytes.

79. The composition of claim **77** wherein the at least one pharmaceutical excipient is water for injection USP.

* * * * *